Yan Juan, Ma Na, Liu Ke-Qin, Qiao Ting-Ting, Wang Yu, Xue Jin-Xing, Hao Xiu-Qing, Zheng Mao-Dong
Department of Pharmacy, the First Affiliated Hospital of Hebei North University, Zhangjiakou, China.
Department of Pharmacy, Taian City Central Hospital Shandong, Taian, China.
Transl Cancer Res. 2022 Sep;11(9):3287-3297. doi: 10.21037/tcr-22-2077.
To study the active ingredient and possible mechanism of Huisheng oral liquid in the treatment of lung cancer by network pharmacology.
The active ingredient and drug targets of Huisheng oral liquid were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and Traditional Chinese Medicine Integrated Database (TCMID), and lung cancer targets were screened using the Gene Expression Omnibus (GEO) database. The drug targets of the effective components of Huisheng oral liquid were matched with disease targets and the obtained intersecting targets were imported into the Search Tool for the Retrieval of Interaction Gene/Proteins (STRING) database to construct a protein-protein interaction (PPI) network. R software and the Kyoto Encyclopedia of Genes and Genomes (KEGG) database were used for Gene Ontology (GO) and KEGG enrichment analyses, and Cytoscape software was used to construct a Huisheng oral liquid component target-lung cancer target network. The function and pathway of the therapeutic target of Huisheng oral liquid for lung cancer were analyzed.
A total of 1,376 differentially expressed genes (DEGs) of lung cancer were obtained, and 185 potential effective components of Huisheng oral liquid in the treatment of lung cancer were obtained, including quercetin, luteolin, kaempferol, and baicalein. There were 36 intersecting targets between Huisheng oral liquid and lung cancer, and the key targets for lung cancer treatment were CDKN1A, CCNB1, MDM2, CDK1, ErbB2, E2F1, EGFR, etc. Huisheng oral liquid mainly regulates the p53 signaling pathway.
The mechanism of Huisheng oral liquid in the treatment of lung cancer is mainly reflected in regulating tumor cell apoptosis, inhibiting angiogenesis, and improving immunity.
运用网络药理学研究回生口服液治疗肺癌的活性成分及可能机制。
通过中药系统药理学数据库与分析平台(TCMSP)和中药综合数据库(TCMID)筛选回生口服液的活性成分及药物靶点,利用基因表达综合数据库(GEO)筛选肺癌靶点。将回生口服液有效成分的药物靶点与疾病靶点进行匹配,把得到的交集靶点导入搜索相互作用基因/蛋白质的工具(STRING)数据库构建蛋白质-蛋白质相互作用(PPI)网络。运用R软件和京都基因与基因组百科全书(KEGG)数据库进行基因本体论(GO)和KEGG富集分析,使用Cytoscape软件构建回生口服液成分靶点-肺癌靶点网络。分析回生口服液治疗肺癌的治疗靶点的功能及通路。
共获得1376个肺癌差异表达基因(DEGs),得到回生口服液治疗肺癌的185种潜在有效成分,包括槲皮素、木犀草素、山柰酚和黄芩苷。回生口服液与肺癌之间有36个交集靶点,肺癌治疗的关键靶点有CDKN1A、CCNB1、MDM2、CDK1、ErbB2、E2F1、EGFR等。回生口服液主要调控p53信号通路。
回生口服液治疗肺癌的机制主要体现在调节肿瘤细胞凋亡、抑制血管生成和提高免疫力。